Targeting Aurora kinases in ovarian cancer

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 1, 2006, Pages 77-85

  Fu, Siqing ^a   Hu, Wei ^a   Kavanagh, John J ^a   Bast Jr , Robert C ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b MDACC   (United States)

Author keywords

Aurora kinase inhibitor; Aurora kinases; Cell cycle; Chemosensitisation; Mitosis; Molecular therapeutic agent; Ovarian cancer

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; CYTOTOXIC AGENT; DOCETAXEL; FLUOROURACIL; GEMCITABINE; HESPERADIN; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PHOSPHOTRANSFERASE; PYRAZOLE DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VX 680;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CARCINOGENESIS; CELL CYCLE; CHROMOSOME SEGREGATION; CYTOKINESIS; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; MITOSIS; NONHUMAN; OVARY CANCER; PROTEIN FUNCTION; RECURRENT CANCER; REGULATORY MECHANISM; REVIEW; SIDE EFFECT;

ANIMALS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 33144484510     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.1.77     Document Type: Review

References (64)

1. JEMAL A, MURRAY T, WARD E et al.: Cancer statistics, 2005. CA Cancer J. Clin. (2005) 55(1):10-30.
2. CANNISTRA SA: Cancer of the ovary. N. Engl. J. Med. (2004) 351(24):2519-2529.
3. CHEESEMAN IM, DESAI A: Cell division: feeling tense enough? Nature (2004) 428(6978):32-33.
4. TIEN AC, LIN MH, SU LJ et al.: Identification of the substrates and interaction proteins of aurora kinases; from a protein-protein interaction model. Mol. Cell Proteomics (2004) 3(1):93-104.
5. GLOVER DM, LEIBOWITZ MH, MCLEAN DA, PARRY H: Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell (1995) 81(1):95-105.
6. GOPALAN G, CHAN CS, DONOVAN PJ: A novel mammalian, mitotic spindle-associated kinase is related to yeast and fly chromosome segregation regulators. J. Cell Biol. (1997) 138(3):643-656.
7. MARUMOTO T, ZHANG D, SAYA H: Aurora-A - a guardian of poles. Nat. Rev. Cancer (2005) 5(1):42-50.
8. CRANE R, GADEA B, LITTLEPAGE L et al.: Aurora A, meiosis and mitosis. Biol. Cell (2004) 96(3):215-229.
9. TATSUKA M, KATAYAMA H, OTA T et al.: Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res. (1998) 58(21):4811-4816.
10. YOKOYAMA. T, GOTA H, IZAWA I et al.: Aurora-B and Rho-kinase/ROCK, the two cleavage furrow kinases, independently regulate the progression of cytokinesis: possible existence of a novel cleavage furrow kinase phosphorylates ezrin/radixin/moesin (ERM). Genes Cells (2005) 10(2):127-137.
11. WHEATLEY SP, HENZING AJ, DODSON H et al.: Aurora-B phosphorylation in vitro identifies a residue of survivin that is essential for its localization and binding to inner centromere protein (INCENP) in vivo. J. Biol. Chem. (2004) 279(7):5655-5660.
12. PASCREAU G, ARLOT-BONNEMAINS Y, PRIGENT C: Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis. Prog. Cell Cycle Res. (2003) 5:369-374.
13. BEARDMORE VA, AHONEN LJ, GORBSKY GJ, KALLIO MJ: Survivin dynamics increases at centromeres during G2/M phase transition and is regulated by micrombule-attachment and Aurora B kinase activity. J. Cell Sci. (2004) 117(Pt 18):4033-4042.
14. LAMPSON MA, KAPOOR TM: The human mitotic checkpoint protein BubR1 regulates chromosome-spindle attachments. Nat. Cell Biol. (2005) 7(1):93-98.
15. HONDA R, KORNER R, NIGG EA: Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol. Biol. Cell (2003) 14(8):3325-3341.
16. DITCHFIELD C, JOHNSON VL, TIGHE A et al.: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. (2003) 161(2):267-280.
17. OHI R, SAPRA T, HOWARD J, MITCHISON TJ: Differentiation of cytoplasmic and meiotic spindle assembly MCAK functions by Aurora B-dependent phosphorylation. Mol. Biol. Cell (2004) 15(6):2895-2906.
18. LI X, SAKASHITA G, MATSUZAKI H et al.: Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C. J. Biol. Chem (2004) 279(45):47201-47211.
19. SASAI K, KATAYAMA H, STENOIEN DL et al.: Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil. Cytoskeleton (2004) 59(4):249-263.
20. BISCHOFF JR, ANDERSON L, ZHU Y et al.: A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. (1998) 17(11):3052-3065.
21. ROYCE ME, XIA W, SAHIN AA et al.: STK15/Aurora-A expression in primary breast rumors is correlated with nuclear grade but not with prognosis. Cancer (2004) 100(1):12-19.
22. GRITSKO TM, COPPOLA D, PACIGA JE et al.: Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin. Cancer Res. (2003) 9(4):1420-1426.
23. MORENO-BUENO G, SANCHEZ-ESTEVEZ C et al.: Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res. (2003) 63(18):5697-5702.
24. TANAKA E, HASHIMOTO Y, ITO T et al.: The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin. Cancer Res. (2005) 11(5):1827-1834.
25. KAMADA E, YAMADA Y, HIRAO T et al.: Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis. Oncol. Rep. (2004) 12(3):593-599.
26. LI D, ZHU J, FIROZI PF et al.: Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin. Cancer Res. (2003) 9(3):991-997.
27. JENG YM, PENG SY, LIN CY, HSU HC: Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin. Cancer Res. (2004) 10(6):2065-2071.
28. FRAIZER GC, DIAZ MF, LEE IL et al.: Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int. J. Oncol. (2004) 25(6):1631-1639.
29. BUSCHHORN HM, KLEIN RR, CHAMBERS SM et al.: Aurora-A overexpression in high-grade PIN lesions and prostate cancer. Prostate (2005) 64(4):341-346.
30. KLEIN A, REICHARDT W. JUNG V et al.: Overexpression and amplification of STK15 in human gliomas. Int. J. Oncol. (2004) 25(6):1789-1794.
31. SORRENTINO R, LIBERTINI S, PALLANTE PL et al.: Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J. Clin. Endocrinol. Metab. (2005) 90(2):928-935.
32. KEEN N, TAYLORS: Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer (2004) 4(12):927-936.
33. MERALDI P, HONDA R, NIGG EA: Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr. Opin. Genet. Dev. (2004) 14(1):29-36.
34. FUJITA Y, SAKAKURA C, SHIMOMURA K et al.: Chromosome arm 20q gains and other genomic alterations in esophageal squamous cell carcinoma, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Hepatogastroenterology (2003) 50(54):1857-1863.
35. GOEPFERT TM, ADIGUN YE, ZHONG L et al.: Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res. (2002) 62(14):4115-4122.
36. KATAYAMA H, BRINKLEY WR, SEN S: The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. (2003) 22(4):451-464.
37. TATSUKA M, SATO S, KITAJIMA S et al.: Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene (2005) 24(6):1122-1127.
38. YANG H, OU CC, FELDMAN RI et al.: Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res. (2004) 64(2):463-467.
39. DU J, HANNON GJ: The centrosomal kinase Aurora-A/STK15 interacts with a putative tumor suppressor NM23-H1. Nucleic Acids Res. (2002) 30(24):5465-5475.
40. MERALDI P, HONDA R, NIGG EA: Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J. (2002) 21(4):483-492.
41. KATAYAMA H, SASAI K, KAWAI H et al.: Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. (2004) 36(1):55-62.
42. YU X, MINTER-DYKHOUSE K, MALUREANU L et al.: Chfr is required for tumor suppression and Aurora A regulation. Nat. Genet. (2005) 37(4):401-406.
43. ZHANG D, HIROTA T. MARUMOTO T et al.: Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene (2004) 23(54):8720-8730.
44. ANAND S, PENRHYN-LOWE S, VENKITARAMAN AR: AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell (2003) 3 (1):51-62.
45. OTA T, SUTO S, KATAYAMA H et al.: Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overespression contributes to chromosome number instability. Cancer Res. (2002) 62(18):5168-5177.
46. TANNER MM, GRENMAN S, KOUL A et al.: Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin. Cancer Res. (2000) 6(5):1833-1839.
47. CHUNG CM, MAN C, JIN Y et al.: Amplification and overexpression of aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells. Mol. Carcinog. (2005) 43(3):165-174.
48. HU W, KAVANAGH JJ, DEAVER M et al.: Frequent overespression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol. Res. (2005) 15(1):49-57.
49. LANDEN CN, IMMANENI A, DEAVER MT et al.: Overexpression of the centrosomal protein aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. J. Clin. Oncol. (Meeting Abstracts) (2005) 23(16 Suppl.):5039.
50. ROJANALA S, HAN H, MUNOZ RM et al.: The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol. Cancer Ther. (2004) 3(4):451-457.
51. MORTLOCK A, KEEN NJ, JUNG FH et al.: Progress in the development of selective inhibitors of Aurora kinases. Curr. Top. Med. Chem. (2005) 5(2):199-213.
52. WARNER SL, MUNOZ RM, KOLLER E et al.: The comparison of aurora A and aurora B as therapeutic targets using antisense oligonucleotides. The 2005 Proceedings of the AACR 96th Annual Meeting, Anaheim, USA (2005) Abstract 591.
53. CAI K, YANG G, ROSEN D et al.: Expression of STK15/BTAK is required for sustained tumor growth through maintenance of genetic stability of cancer cells. The 2005 Proceedings of the AACR 96th Annual Meeting, Anaheim, USA (2005) Abstract 127.
54. MORTLOCK AA. KEEN NJ, JUNG FH et al.: Progress in the development of selective inhibitors of aurora kinases. Curr. Top. Med. Chem. (2005) 5(8):807-821.
55. FANCELLI D, BERTA D, BINDI S et al.: Potent and selective aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J. Med. Chem. (2005) 48(8):3080-3084.
56. YANG H, BURKE T, DEMPSEY J et al.: Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase. FEBS Lett. (2005) 579(16):3385-3391.
57. GADEA BB, RUDERMAN JV: Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts. Mol. Biol. Cell (2005) 16(3):1305-1318.
58. HAUF S, COLE RW, LATERRA S et al.: The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-micrombule attachment and in maintaining the spindle assembly checkpoint. J. Cell. Biol. (2003) 161(2):281-294.
59. SESSA F, MAPELLI M, CIFERRI C et al.: Mechanism of Aurora B Activation by INCENP and Inhibition by Hesperadin. Mol. Cell (2005) 18(3):379-391.
60. HARRINGTON EA, BEBBINGTON D, MOORE J et al.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. (2004) 10 (3):262-267.
61. CHEETHAM GM, KNEGTEL RM, COLL JT et al.: Crystal structure of aurora-2, an oncogenic serine/threonine kinase. J. Biol. Chem. (2002) 277(45):42419-42422.
62. HATA T, FURUKAWA T, SUNAMURA M et al.: RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. (2005) 65(7):2899-2905.
63. NAIR J, TSE N, KEEN N, SCHWARTZ G: A Novel Aurora B kinase inhibitor with potent anticancer activity either as a single agent or in combination with chemotherapy. JCO ASCO Annual Meeting Proceedings (2004) 22(14S):9568.
64. WARNER SL, BEARSS DJ, HAN H, VON HOFF DD: Targeting Aurora-2 kinase in cancer. Mol. Cancer Ther. (2003) 2(6):589-595.